Interstitial Lung Diseases and Non-Small Cell Lung Cancer: Particularities in Pathogenesis and Expression of Driver Mutations

Overview

Journal Genes (Basel)

Publisher MDPI

Date 2024 Jul 27

PMID 39062713

Authors

Fotios Sampsonas

Pinelopi Bosgana

Vasiliki Bravou

Argyrios Tzouvelekis

Foteinos-Ioannis Dimitrakopoulos

Eleni Kokkotou

Affiliations

Soon will be listed here.

Abstract

Introduction: Interstitial lung diseases are a varied group of diseases associated with chronic inflammation and fibrosis. With the emerging and current treatment options, survival rates have vastly improved. Having in mind that the most common type is idiopathic pulmonary fibrosis and that a significant proportion of these patients will develop lung cancer as the disease progresses, prompt diagnosis and personalized treatment of these patients are fundamental.

Scope And Methods: The scope of this review is to identify and characterize molecular and pathogenetic pathways that can interconnect Interstitial Lung Diseases and lung cancer, especially driver mutations in patients with NSCLC, and to highlight new and emerging treatment options in that view.

Results: Common pathogenetic pathways have been identified in sites of chronic inflammation in patients with interstitial lung diseases and lung cancer. Of note, the expression of driver mutations in EGFR, BRAF, and KRAS G12C in patients with NSCLC with concurrent interstitial lung disease is vastly different compared to those patients with NSCLC without Interstitial Lung Disease.

Conclusions: NSCLC in patients with Interstitial Lung Disease is a challenging diagnostic and clinical entity, and a personalized medicine approach is fundamental to improving survival and quality of life. Newer anti-fibrotic medications have improved survival in IPF/ILD patients; thus, the incidence of lung cancer is going to vastly increase in the next 5-10 years.

References

Konigshoff M, Balsara N, Pfaff E, Kramer M, Chrobak I, Seeger W . Functional Wnt signaling is increased in idiopathic pulmonary fibrosis. PLoS One. 2008; 3(5):e2142. PMC: 2374879. DOI: 10.1371/journal.pone.0002142. View

Chen R, Zhao W, Fang C, Yang X, Ji M . Histone methyltransferase SETD2: a potential tumor suppressor in solid cancers. J Cancer. 2020; 11(11):3349-3356. PMC: 7097956. DOI: 10.7150/jca.38391. View

Maher T, Bendstrup E, Dron L, Langley J, Smith G, Khalid J . Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res. 2021; 22(1):197. PMC: 8261998. DOI: 10.1186/s12931-021-01791-z. View

Jafarinezhad A, YektaKooshali M . Lung cancer in idiopathic pulmonary fibrosis: A systematic review and meta-analysis. PLoS One. 2018; 13(8):e0202360. PMC: 6095562. DOI: 10.1371/journal.pone.0202360. View

Borie R, Tabeze L, Thabut G, Nunes H, Cottin V, Marchand-Adam S . Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis. Eur Respir J. 2016; 48(6):1721-1731. DOI: 10.1183/13993003.02115-2015. View

Ozawa Y, Suda T, Naito T, Enomoto N, Hashimoto D, Fujisawa T . Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology. 2009; 14(5):723-8. DOI: 10.1111/j.1440-1843.2009.01547.x. View

Johkoh T, Sakai F, Kusumoto M, Arakawa H, Harada R, Ueda M . Association between baseline pulmonary status and interstitial lung disease in patients with non-small-cell lung cancer treated with erlotinib--a cohort study. Clin Lung Cancer. 2014; 15(6):448-54. DOI: 10.1016/j.cllc.2014.06.003. View

King C, Borrello I, Bellot F, Comoglio P, Schlessinger J . Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3. EMBO J. 1988; 7(6):1647-51. PMC: 457148. DOI: 10.1002/j.1460-2075.1988.tb02991.x. View

Perelas A, Silver R, Arrossi A, Highland K . Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med. 2020; 8(3):304-320. DOI: 10.1016/S2213-2600(19)30480-1. View

10.

Kawasaki H, Ogura T, Yokose T, Nagai K, Nishiwaki Y, Esumi H . p53 gene alteration in atypical epithelial lesions and carcinoma in patients with idiopathic pulmonary fibrosis. Hum Pathol. 2001; 32(10):1043-9. DOI: 10.1053/hupa.2001.28246. View

11.

Vallath S, Hynds R, Succony L, Janes S, Giangreco A . Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities. Eur Respir J. 2014; 44(2):513-22. PMC: 4209854. DOI: 10.1183/09031936.00146413. View

12.

Frank A, Dagogo-Jack I, Dobre I, Tait S, Schumacher L, Fintelmann F . Management of Lung Cancer in the Patient with Interstitial Lung Disease. Oncologist. 2022; 28(1):12-22. PMC: 9847545. DOI: 10.1093/oncolo/oyac226. View

13.

Zhang Y, Wang J . Cellular and Molecular Mechanisms in Idiopathic Pulmonary Fibrosis. Adv Respir Med. 2023; 91(1):26-48. PMC: 9952569. DOI: 10.3390/arm91010005. View

14.

Korfhagen T, Swantz R, Wert S, McCarty J, Kerlakian C, Glasser S . Respiratory epithelial cell expression of human transforming growth factor-alpha induces lung fibrosis in transgenic mice. J Clin Invest. 1994; 93(4):1691-9. PMC: 294218. DOI: 10.1172/JCI117152. View

15.

Hatabu H, Hunninghake G, Richeldi L, Brown K, Wells A, Remy-Jardin M . Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. Lancet Respir Med. 2020; 8(7):726-737. PMC: 7970441. DOI: 10.1016/S2213-2600(20)30168-5. View

16.

Jankowich M, Rounds S . Combined pulmonary fibrosis and emphysema syndrome: a review. Chest. 2012; 141(1):222-231. PMC: 3251269. DOI: 10.1378/chest.11-1062. View

17.

Grodkiewicz M, Koziel P, Chmielewska I, Korbel M, Milanowski J . Small Cell Lung Cancer in the Course of Idiopathic Pulmonary Fibrosis-Case Report and Literature Review. Curr Oncol. 2022; 29(7):5077-5083. PMC: 9318736. DOI: 10.3390/curroncol29070401. View

18.

Choi J, Park J, Tsagkogeorga G, Yanagita M, Koo B, Han N . Inflammatory Signals Induce AT2 Cell-Derived Damage-Associated Transient Progenitors that Mediate Alveolar Regeneration. Cell Stem Cell. 2020; 27(3):366-382.e7. PMC: 7487779. DOI: 10.1016/j.stem.2020.06.020. View

19.

Guyard A, Danel C, Theou-Anton N, Debray M, Gibault L, Mordant P . Morphologic and molecular study of lung cancers associated with idiopathic pulmonary fibrosis and other pulmonary fibroses. Respir Res. 2017; 18(1):120. PMC: 5472872. DOI: 10.1186/s12931-017-0605-y. View

20.

Marmai C, Sutherland R, Kim K, Dolganov G, Fang X, Kim S . Alveolar epithelial cells express mesenchymal proteins in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2011; 301(1):L71-8. PMC: 3129898. DOI: 10.1152/ajplung.00212.2010. View